Our lead Sarcoidosis Virtual Group moderator, Frank Rivera, is nationally recognized in both the sarcoidosis and rare disease communites. Frank is an amazing and inspirational individual who has just self published his story, ‘Walking in Silent Pain’ on Amazon. To read more about the book, please click here.
And if you are on Amazon, and have not already signed up for Amazon Smile, please do so and nominate Answer Cancer Foundation. For every dollar you spend on Amazon or Amazon Prime, they donate a half-cent to us at no expense to you. It mounts up, so please particpate.
Editor’s Pick – ATM and TP53 mutations may increase risk of radiation damage.
Treatment after 2nd line anti-androgen fails; CARD trial & Jevtana/cabazitaxel; finding a trial close to home; is chemo best early or late?; somatic mutations can change; osteopenia – what to do; ADT driven anemia; ATM & TP53 mutations may increase risk for radiation damage; dealing with pain before and after cancer Dx
Back in mid-2012, the US Preventative Services Task Force first made the following recommendation with an associated DGrade:
The U.S. Preventive Services Task Force (USPSTF) recommends against prostate-specific antigen (PSA)–based screening for prostate cancer.
At the time, prostate cancer advocates objected strongly, warning it would result in many more men diagnosed de novo metastatic, and ultimately more disease specific deaths.
Sadly, we have seen this manifested, especially with respect to younger men. AnCan clearly sees the trend along with a lack of support for the particular needs expressed by younger men living with advanced prostate cancer. Along with our partner, UsTOO, we have established an Under-60 Advanced Prostate Cancer Virtual Group to address these needs.
——————————————————————————————————–
2nd Thursday of each month at 7 pm Eastern in The Barniskis Room (222-583-973)
Back in mid-2012, the US Preventative Services Task Force first made the following recommendation with an associated DGrade:
The U.S. Preventive Services Task Force (USPSTF) recommends against prostate-specific antigen (PSA)–based screening for prostate cancer.
At the time, prostate cancer advocates objected strongly, warning it would result in many more men diagnosed de novo metastatic, and ultimately more disease specific deaths.
Sadly, we have seen this manifested, especially with respect to younger men. AnCan clearly sees the trend along with a lack of support for the particular needs expressed by younger men living with advanced prostate cancer. Along with our partner, UsTOO, we have established an Under-60 Advanced Prostate Cancer Virtual Group to address these needs.
——————————————————————————————————–
2nd Thursday of each month at 7 pm Eastern in The Barniskis Room (222-583-973)
Back in mid-2012, the US Preventative Services Task Force first made the following recommendation with an associated DGrade:
The U.S. Preventive Services Task Force (USPSTF) recommends against prostate-specific antigen (PSA)–based screening for prostate cancer.
At the time, prostate cancer advocates objected strongly, warning it would result in many more men diagnosed de novo metastatic, and ultimately more disease specific deaths.
Sadly, we have seen this manifested, especially with respect to younger men. AnCan clearly sees the trend along with a lack of support for the particular needs expressed by younger men living with advanced prostate cancer. Along with our partner, UsTOO, we have established an Under-60 Advanced Prostate Cancer Virtual Group to address these needs.
——————————————————————————————————–
2nd Thursday of each month at 7 pm Eastern in The Barniskis Room (222-583-973)